This dynamic, coupled with the increasing sophistication and specialization of the CRO ecosystem, has enabled the creation of single-asset deals with defined liquidity paths via structured buyouts.
FORBES: New Biotech Corporate Structures: Possible Alternatives For Discovery Platforms and Product Financings